Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for InSilico Medicine Cayman TopCo's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:O15's 5-Year Yield-on-Cost % is not ranked *
in the Software industry.
Industry Median: 3.08 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
InSilico Medicine Cayman TopCo (FRA:O15) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
InSilico Medicine Cayman TopCo 5-Year Yield-on-Cost % Related Terms
FRA:O15 vs MSFT, ORCL, PLTR: 5-Year Yield-on-Cost % Comparison
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo 5-Year Yield-on-Cost % vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's 5-Year Yield-on-Cost % falls into.
InSilico Medicine Cayman TopCo 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
InSilico Medicine Cayman TopCo (FRA:O15) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 27, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 997 companies in the Software industry.
Is InSilico Medicine Cayman TopCo's 5-Year Yield-on-Cost % too high?
InSilico Medicine Cayman TopCo's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 997 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's 5-Year Yield-on-Cost % compare to MSFT and ORCL?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #999999 out of 997 companies for 5-Year Yield-on-Cost %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Software company?
The median 5-Year Yield-on-Cost % among Software companies is 3.08, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median 5-Year Yield-on-Cost % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score
Get the complete analysis for FRA:O15
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O15 has been successfully added to your 
